BSE:524742

Stock Analysis Report

Executive Summary

Caplin Point Laboratories Limited produces, develops, markets, and exports generic formulations and branded products in India and internationally.

Snowflake

Fundamentals

Flawless balance sheet with proven track record.


Similar Companies

Share Price & News

How has Caplin Point Laboratories's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.5%

524742

3.0%

IN Pharmaceuticals

3.1%

IN Market


1 Year Return

-7.4%

524742

-18.9%

IN Pharmaceuticals

3.7%

IN Market

Return vs Industry: 524742 exceeded the Indian Pharmaceuticals industry which returned -18.9% over the past year.

Return vs Market: 524742 underperformed the Indian Market which returned 3.7% over the past year.


Shareholder returns

524742IndustryMarket
7 Day-2.5%3.0%3.1%
30 Day-6.5%-4.2%5.7%
90 Day-5.8%-2.5%1.4%
1 Year-6.9%-7.4%-18.2%-18.9%5.9%3.7%
3 Year13.6%12.3%-26.1%-27.6%22.3%16.0%
5 Year373.9%359.7%-11.7%-14.3%42.5%28.9%

Price Volatility Vs. Market

How volatile is Caplin Point Laboratories's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Caplin Point Laboratories undervalued compared to its fair value and its price relative to the market?

15.76x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Undervalued: 524742 (₹394.6) is trading above our estimate of fair value (₹66.22)

Significantly Undervalued: 524742 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 524742 is poor value based on its PE Ratio (15.8x) compared to the Pharmaceuticals industry average (15.8x).

PE vs Market: 524742 is poor value based on its PE Ratio (15.8x) compared to the Indian market (13.2x).


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate 524742's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 524742 is overvalued based on its PB Ratio (5x) compared to the IN Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is Caplin Point Laboratories forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-0.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 524742's earnings are forecast to decline over the next 3 years (-0.4% per year).

Earnings vs Market: 524742's earnings are forecast to decline over the next 3 years (-0.4% per year).

High Growth Earnings: 524742's earnings are forecast to decline over the next 3 years.

Revenue vs Market: 524742's revenue (13.2% per year) is forecast to grow faster than the Indian market (11.4% per year).

High Growth Revenue: 524742's revenue (13.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if 524742's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Caplin Point Laboratories performed over the past 5 years?

36.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 524742's earnings have grown significantly by 36.4% per year over the past 5 years.

Accelerating Growth: 524742's earnings growth over the past year (29.8%) is below its 5-year average (36.4% per year).

Earnings vs Industry: 524742 earnings growth over the past year (29.8%) exceeded the Pharmaceuticals industry 14.4%.


Return on Equity

High ROE: 524742's Return on Equity (29.9%) is considered high.


Return on Assets

ROA vs Industry: 524742 has a higher Return on Assets than the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: 524742's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Caplin Point Laboratories's financial position?


Financial Position Analysis

Short Term Liabilities: 524742's short term assets (₹4.9B) exceeds its short term liabilities (₹861.1M)

Long Term Liabilities: 524742's short term assets (4.9B) exceeds its long term liabilities (234.2M)


Debt to Equity History and Analysis

Debt Level: 524742's debt to equity ratio (0.05%) is considered satisfactory

Reducing Debt: 524742's debt to equity ratio has reduced from 5.4% to 0.05% over the past 5 years.

Debt Coverage: 524742's debt is well covered by operating cash flow (29088.2%).

Interest Coverage: 524742's interest payments on its debt are well covered by EBIT (3811.9x coverage).


Balance Sheet

Inventory Level: 524742 has a high level of physical assets or inventory.

Debt Coverage by Assets: 524742's debt is covered by short term assets (assets are 1721.367500x debt).


Next Steps

Dividend

What is Caplin Point Laboratories's current dividend yield, its reliability and sustainability?

0.56%

Current Dividend Yield


Dividend Yield vs Market

company0.6%marketbottom25%0.6%markettop25%2.5%industryaverage0.9%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: 524742's dividend (0.56%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.6%).

High Dividend: 524742's dividend (0.56%) is low compared to the top 25% of dividend payers in the Indian market (2.48%).

Stable Dividend: Whilst dividend payments have been stable, 524742 has been paying a dividend for less than 10 years.

Growing Dividend: 524742's dividend payments have increased, but the company has only paid a dividend for 9 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (8.8%), 524742's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of Caplin Point Laboratories's salary, the management and board of directors tenure and is there insider trading?

4.6yrs

Average management tenure


CEO

Sridhar Ganesan (64yo)

4.6yrs

Tenure

₹5,690,000

Compensation

Dr. Sridhar Ganesan has been the Managing Director of Caplin Point Laboratories Ltd since March 28, 2015. Dr. Ganesan has been Whole Time Director of Caplin Point Laboratories Ltd since August 25, 2014. Dr ...


CEO Compensation Analysis

Compensation vs. Market: Sridhar's total compensation ($USD79.68K) is about average for companies of similar size in the Indian market ($USD317.97K).

Compensation vs Earnings: Sridhar's compensation has been consistent with company performance over the past year.


Management Age and Tenure

4.6yrs

Average Tenure

Experienced Management: 524742's management team is considered experienced (4.6 years average tenure).


Board Age and Tenure

5.3yrs

Average Tenure

67yo

Average Age

Experienced Board: 524742's board of directors are considered experienced (5.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Buy₹3,313,98222 Feb 19
C. Paarthipan
EntityIndividual
Role
Chairman of the Board
Non-Executive Chairman
Shares10,000
Max Price₹331.40

Ownership Breakdown


Management Team

  • Partheeban Siddarth

    Chief Operating Officer

    • Tenure: 8.2yrs
    • Compensation: ₹1.82m
  • V. Natarajan

    Head of Formulation & Development -Injectibles

    • Tenure: 0yrs
  • Sridhar Ganesan (64yo)

    MD & Whole Time Director

    • Tenure: 4.6yrs
    • Compensation: ₹5.69m
  • S. Kumar

    Company Secretary & Compliance Officer

    • Tenure: 0yrs
    • Compensation: ₹794.00k
  • D. Muralidharan

    Chief Financial Officer

    • Tenure: 3.7yrs
    • Compensation: ₹2.65m

Board Members

  • V. Thirumalai (78yo)

    Non-Executive Independent Director

    • Tenure: 25.3yrs
    • Compensation: ₹200.00k
  • D. Mishra (64yo)

    Non-Executive Non-Independent Director

    • Tenure: 11.8yrs
    • Compensation: ₹80.00k
  • C. Paarthipan (67yo)

    Non-Executive Chairman

    • Tenure: 0yrs
  • R. Ravichandran (62yo)

    Non-Executive Independent Director

    • Tenure: 5.4yrs
    • Compensation: ₹300.00k
  • Sridhar Ganesan (64yo)

    MD & Whole Time Director

    • Tenure: 4.6yrs
    • Compensation: ₹5.69m
  • K. John (67yo)

    Non-Executive Independent Director

    • Tenure: 5.2yrs
    • Compensation: ₹200.00k
  • R. Viswanathan (67yo)

    Non-Executive Independent Director

    • Tenure: 4.4yrs
    • Compensation: ₹100.00k
  • K. Prasad (71yo)

    Non-Executive Independent Director

    • Tenure: 4.7yrs
    • Compensation: ₹260.00k
  • D. Sathyanarayanan (60yo)

    Non-Executive Independent Director

    • Tenure: 2.9yrs
    • Compensation: ₹220.00k

Company Information

Caplin Point Laboratories Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Caplin Point Laboratories Limited
  • Ticker: 524742
  • Exchange: BSE
  • Founded: 1990
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹30.594b
  • Shares outstanding: 75.64m
  • Website: https://www.caplinpoint.net

Location

  • Caplin Point Laboratories Limited
  • NARBHAVI
  • No. 3, Lakshmanan Street
  • Chennai
  • Tamil Nadu
  • 600017
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
524742BSE (Mumbai Stock Exchange)YesEquity SharesININRFeb 2002
CAPPLNSEI (National Stock Exchange of India)YesEquity SharesININRFeb 2002

Biography

Caplin Point Laboratories Limited produces, develops, markets, and exports generic formulations and branded products in India and internationally. It provides liquid injections, lyophilised injections, opt ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 12:38
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.